Profile data is unavailable for this security.
About the company
Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
- Revenue in EUR (TTM)3.67bn
- Net income in EUR357.60m
- Incorporated1967
- Employees14.65k
- LocationBiomerieux SA376, chemin de l'OrmeCRAPONNE 69280FranceFRA
- Phone+33 478872000
- Fax+33 478872090
- Websitehttps://www.biomerieux.fr/
More ▼
Mergers & acquisitions
| Acquired company | BIM:PAR since announced | Transaction value |
|---|---|---|
| Lumed Inc | 0.70% | 9.63m |
Data delayed at least 15 minutes, as of Apr 25 2024 10:46 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BACHEM HOLDING AG | 589.66m | 114.25m | 6.20bn | 2.01k | 53.99 | 4.60 | 38.65 | 10.52 | 1.50 | 1.50 | 7.73 | 17.61 | 0.3765 | 1.23 | 3.33 | 287,794.60 | 7.29 | 8.85 | 8.17 | 10.28 | 30.65 | 31.63 | 19.38 | 19.74 | 3.04 | 29.80 | 0.0003 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
| Croda International Plc | 1.97bn | 199.20m | 7.57bn | 5.85k | 38.05 | 2.76 | 21.79 | 3.84 | 1.22 | 1.22 | 12.12 | 16.85 | 0.4713 | 2.40 | 4.39 | 289,559.10 | 4.79 | 10.80 | 5.42 | 12.51 | 43.08 | 46.41 | 10.16 | 18.64 | 1.77 | 17.07 | 0.2307 | 43.44 | -18.90 | 4.09 | -73.66 | -6.42 | 12.78 | 4.11 |
| Swedish Orphan Biovitrum AB (publ) | 1.90bn | 206.98m | 8.11bn | 1.77k | 36.65 | 2.67 | 16.93 | 4.27 | 7.27 | 7.27 | 67.83 | 99.68 | 0.3497 | 1.38 | 4.25 | 12,484,200.00 | 3.80 | 5.93 | 5.20 | 7.60 | 77.57 | 77.42 | 10.88 | 16.61 | 0.4607 | 4.04 | 0.3769 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
| Qiagen NV | 1.84bn | 319.06m | 8.59bn | 5.97k | 27.05 | 2.40 | 16.81 | 4.68 | 1.43 | 1.43 | 8.21 | 16.08 | 0.3169 | 1.93 | 5.38 | 307,902.00 | 5.50 | 5.41 | 6.60 | 6.53 | 62.77 | 64.65 | 17.37 | 16.35 | 1.62 | -- | 0.2839 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
| Ipsen SA | 3.31bn | 617.10m | 9.41bn | 5.33k | 15.19 | 2.43 | 9.83 | 2.85 | 7.39 | 7.72 | 39.66 | 46.25 | 0.554 | 1.99 | 5.23 | 620,920.20 | 10.48 | 9.71 | 13.93 | 13.33 | 82.72 | 82.76 | 18.91 | 16.02 | 0.989 | 30.43 | 0.089 | 19.23 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
| Recordati Industria Chmc Frmctc SpA | 2.08bn | 389.21m | 10.45bn | 4.46k | 26.55 | 6.11 | 19.44 | 5.02 | 1.88 | 1.88 | 10.08 | 8.19 | 0.5075 | 1.59 | 5.16 | 467,414.40 | 9.48 | 11.67 | 12.40 | 15.02 | 68.32 | 70.43 | 18.69 | 21.45 | 0.795 | 8.34 | 0.5175 | 42.46 | 12.36 | 9.02 | 24.61 | 4.50 | 81.68 | 5.46 |
| Eurofins Scientific SE | 6.51bn | 516.50m | 10.97bn | 61.80k | 21.78 | 2.15 | 9.68 | 1.68 | 2.61 | 1.30 | 32.92 | 26.44 | 0.6213 | 36.20 | 4.79 | 105,417.60 | 5.41 | 7.49 | 6.70 | 9.36 | 20.93 | 23.78 | 8.71 | 11.23 | 1.38 | 8.43 | 0.4332 | 19.28 | -2.94 | 11.49 | -21.53 | 10.91 | 8.58 | 11.66 |
| BioMerieux SA | 3.67bn | 357.60m | 11.92bn | 14.65k | 33.46 | 3.17 | 19.34 | 3.24 | 3.01 | 3.01 | 30.93 | 31.76 | 0.7036 | 1.97 | 5.00 | 250,815.60 | 6.18 | 9.30 | 7.88 | 12.31 | 55.99 | 56.51 | 8.78 | 12.38 | 1.19 | -- | 0.1215 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
| Sandoz Group AG | -102.14bn | -102.14bn | 13.52bn | 23.85k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.23 | -- | -90.92 | -- | -- | -- |
| Genmab A/S | 2.21bn | 583.50m | 17.48bn | 2.20k | 29.86 | 4.08 | -- | 7.92 | 66.05 | 66.05 | 249.95 | 483.85 | 0.5037 | -- | 3.09 | 7,474,592.00 | 13.31 | 17.43 | 14.25 | 18.59 | 55.82 | -- | 26.42 | 35.87 | 13.32 | -- | 0.0238 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
Data as of Apr 25 2024. Currency figures normalised to Biomerieux SA's reporting currency: Euro EUR
7.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 1.52m | 1.28% |
| Oddo BHF Asset Management SASas of 28 Mar 2024 | 1.51m | 1.28% |
| Candriam Belgium SAas of 31 Mar 2024 | 1.21m | 1.02% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.03m | 0.87% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 818.16k | 0.69% |
| Financi�re de l'�chiquier SAas of 30 Jun 2023 | 739.84k | 0.63% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 648.06k | 0.55% |
| BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 596.63k | 0.50% |
| DNCA Finance SAas of 30 Jun 2023 | 565.63k | 0.48% |
| Geode Capital Management LLCas of 18 Apr 2024 | 517.49k | 0.44% |
More ▼
Data from 31 Dec 2023 - 17 Apr 2024Source: FactSet Research Systems Inc.
